ASH 2020 | Myelofibrosis highlights at ASH 2020
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides his highlights on the latest myelofibrosis data presented at ASH 2020. Dr Bose discussed updated safety and efficacy data from arm 3 of the ongoing Phase II MANIFEST study (NCT02158858), which involved JAK-inhibitor-naïve patients being treated with CPI-0610 and ruxolitinib in combination, resulting in high spleen and symptom response rates. Dr Bose goes on to discuss the latest data presented on imetelstat, an intravenously-administered telomerase inhibitor, which has shown positive efficacy results in the post-ruxolitinib setting, with a prolonged median survival. Dr Bose also discusses data presented for bomedemstat, navitoclax and momelotinib. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Prithviraj Bose, MD, has received honoraria from Incyte Corporation and Celgene Corporation (now BMS); has received consulting fees from Incyte Corporation, Celgene Corporation, Blueprint Medicines, CTI BioPharma and Kartos Therapeutics; and has received research funding from Incyte Corporation, Celgene Corporation, Blueprint Medicines, CTI BioPharma, Kartos Therapeutics, Constellation Pharmaceuticals, Astellas, Pfizer, NS Pharma and Promedior.
